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Abstract
The response of the immune system to probiotics remains controversial. Some strains modulate the cytokine production of
dendritic cells (DCs) in vitro and induce a regulatory response, while others induce conversely a pro-inflammatory response.
These strain-dependent effects are thought to be linked to specific interactions between bacteria and pattern recognition
receptors. We investigated the effects of a well characterized probiotic strain, Lactobacillus rhamnosus Lcr35, on human
monocyte-derived immature DCs, using a wide range of bacterial concentrations (multiplicity of infection, MOI, from 0.01 to
100). DNA microarray and qRT-PCR analysis showed that the probiotic induced a large-scale change in gene expression
(nearly 1,700 modulated genes, with 3-fold changes), but only with high doses (MOI, 100). The upregulated genes were
mainly involved in immune response and identified a molecular signature of inflammation according to the model of Torri.
Flow cytometry analysis also revealed a dose-dependent maturation of the DC membrane phenotype, until DCs reached a
semi-mature state, with an upregulation of the membrane expression of CD86, CD83, HLA-DR and TLR4, associated with a
down-regulation of DC-SIGN, MR and CD14. Measurement of the DC-secreted cytokines showed that Lcr35 induced a strong
dose-dependent increase of the pro-Th1/Th17 cytokine levels (TNFa, IL-1b, IL-12p70, IL-12p40 and IL-23), but only a low
increase in IL-10 concentration. The probiotic L. rhamnosus Lcr35 therefore induce a dose-dependent immunomodulation of
human DCs leading, at high doses, to the semi-maturation of the cells and to a strong pro-inflammatory effect. These results
contribute to a fuller understanding of the mechanism of action of this probiotic, and thus of its potential clinical indications
in the treatment of either infectious or IgE-dependent allergic diseases.
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Introduction
Dendritic cells (DCs) are antigen presenting cells that play a
critical role in the orchestration of the adaptative immune response
by inducing both tolerance and immunity [1,2]. The current
paradigm is that this dual role is the result of the division of the total
DC population into a network of DC subsets with distinct functions
[3,4]. Immature DCs reside in peripheral tissues, such as the gut
mucosa, where they sense the microenvironment via pattern
recognition receptors (PRRs), including toll-like receptors (TLRs)
and C-type lectin receptors (CLRs), which recognize pathogen
products called pathogen-associated molecular patterns (PAMPs)
[5]. This antigenic stimulation triggers a DC maturation process
with up-regulation or down-regulation of membrane molecules
CD83, CD86, HLA-DR and DC-SIGN respectively, and cytokine
production. The activation of the DCs by several PAMPs with
antagonistic or synergistic effects, through distinct PRRs, modulates
their differentiation, which secondarily determines the polarization
of the effector T cell responses, i.e. Th1, Th2, Th17 or T regulatory
(Treg) responses [6]. An important factor in this process is cytokine
production by DCs. When they produce IL-12, polarization is
driven towards Th1 cells, whereas the synthesis of IL-1b, IL-6,
TGFb and IL-23 leads to Th17 cells, and that of IL-10, towards
Treg cells [7,8]. Recently, Torri et al. proposed a model of DCs gene
expression profiling (a pattern of 54 tested genes) that can identify of
the anti- or pro-inflammatory effects of tested bacteria or molecules
on DC activity [9].
The human gastrointestinal tract is continuously exposed to
several hundreds of commensal bacteria species from the intestinal
flora. Yet, under physiological conditions, little or no inflammation
occurs in the mucosal barrier. The understanding of the direct
interactions between commensal bacteria and DCs is especially
important to know how the immune system of the gut is locally
able to distinguish them from pathogens and to elicit a tolerogenic
response. Among the commensal intestinal bacteria, some strains
of lactobacilli, named probiotics, are known to confer benefit to
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human health. The mechanisms of probiotic actions include
immune modulation of DCs, but their effects on DCs maturation
are not well understood and vary widely according to the bacteria
used [10]. In vitro, some strains modulate the production of
cytokines by dendritic cells (or monocytes) and induce a regulatory
response by eliciting the production of IL-10, whereas others
induce Th1-mediated pro-inflammatory responses through the
production of IL-12 [11–14]. These strain-dependent effects are
probably linked to interactions between specific bacterial surface
structures and the PRRs, such as the DC-SIGN, a member of the
CLR family, which interacts with certain strains, but not with
others [13]. Nevertheless, most studies reporting immune effect of
probiotics have used very different bacteria/DC ratios [11–14].
We cannot rule out the possibility that these differences in ratio
influenced the DC maturation process and therefore their response
to the bacteria. It is noteworthy that the in vivo effects of probiotics
are generally observed after regular daily medication, suggesting a
significant dose effect.
To adress this question, we investigated the effects of a well
characterized probiotic strain, Lactobacillus rhamnosus Lcr35 [15–
17], on human monocyte-derived immature DCs. A variety of
techniques, from global gene transcription profile to expression of
membrane and soluble proteins analysis, was used to characterize
the DCs responses after contact with Lcr35. All assays were
performed with a wide range of Lcr35 concentrations. We were
thus able to observe differences according to the dose of probiotic
bacteria used, and in particular a strong pro-inflammatory, pro-
Th1 and pro-Th17 effects at high doses.
Methods
Bacterial strain and culture conditions
Lactobacillus rhamnosus 35 (Lcr35) was grown without agitation in
De Man, Rogosa, Sharpe (MRS) medium (BD DifcoTM, BD
diagnostics, Le Pont-De-Claix, France) at 37uC overnight.
Bacterial cells were harvested by centrifugation (11,0006 g for
10 min), and the pellet resuspended in DC culture medium (RPMI
1640). Optical measures (Mac Farland) were performed to adjust
the final concentration of the bacterial suspension, and the exact
number of colony forming units (CFU) was determined by plating
serial dilutions of the inocula onto MRS plates. Before being
added to the DC samples, the bacterial cells were inactivated by
exposure to UV for 40 min. Successful inactivation of bacteria was
assessed by plating the final suspension on agar plates.
Ethic statement
Human cells used in this study were generated from the buffy-
coat of 14 healthy volunteers obtained from the local French blood
agency (Etablissement Franc¸ais du Sang (EFS), Saint-Etienne).
Blood donation requires the systematic information of the
volunteers (article R.1221-5 of the Public Health Code, 01/12/
2009 and 06/11/2006 decrees) and written informed consents
were obtained by EFS from all donors involved in our study.
In vitro differentiation of monocyte-derived dendritic
cells
DCs were generated from peripheral blood mononuclear cells
(PBMC). Briefly, PBMCs were isolated from the buffy-coat of
healthy volunteers by Ficoll-Histopaque (Sigma, Saint-Quentin
Fallavier, France) density gradient centrifugation. For phenotypic
assays, the PBMCs were washed twice with RPMI 1640 (Cambrex
Bio Science, Verviers, Belgium), and the monocytes were then
isolated by adherence (2 hours). The surface of the plates (75 cm2
flasks, BD Falcon, Le Pont de Claix, France) was precoated with
1 mg/mL Poly-L Lysine (PLL, Sigma) for 2 h at 4uC. On the other
hand for transcriptional assays, the PBMCs were resuspended in
PBS supplemented with 2% FCS and 1 mM EDTA at a final
concentration of 5.107 cells/ml and the monocytes were purified
by negative selection using the EasySepH Human Monocyte
Enrichment Kit as recommended by the manufacturer (StemCell
Technologies, Grenoble, France). In both cases, the monocytes
were then cultured for 5 days in RPMI 1640 supplemented with
1% L-glutamine (Sigma), 10% FCS (Biowest-Abcys, Paris, France)
and 0.5% penicillin-streptomycin (Sigma) and containing 500
U/mL IL4 (R&D systems, Lille, France) and 800 U/mL
granulocyte-macrophage colony-stimulating factor (GM-CSF
from R&D systems). After 3 days of incubation, one-half volume
of fresh medium containing 26 doses of IL4 and GM-CSF was
added to each well. The purity of the dendritic cells was assessed
by flow cytometry analysis using a marker highly specific of the
DC lineage, the DC-SIGN, and was always above 90% (figure S1).
Transcriptional assays
On day 6, immature dendritic cells were washed twice with
PBS, resuspended in fresh growth medium without antibiotic and
seeded at a concentration of 106 cells/cm2 in 24-well Nunc tissue
plates. Freshly grown bacteria were washed and resuspended in
PBS to obtain L. rhamnosus Lcr35 suspensions with concentrations
of 109 and 106 CFU/ml. Ten microliters of bacterial suspensions,
i.e 107 or 104 CFU, or PBS without bacteria (control) were added
to each well, permitting to obtain a multiplicity of infection (MOI)
of 10, 0.01 or 0 (control) respectively, and the tissue culture plates
were incubated for 3 hours to allow interaction of L. rhamnosus
Lcr35 with the cells. The DCs were rinced twice with PBS before
proceeding to total RNA extraction using TRIzolH reagent as
recommended by the supplier (Invitrogen) with slight modifica-
tions. Briefly, cells were homogenized and lysed by addition of
400 ml of TRIzolH reagent to each well, repetitive pipetting
followed by incubation for 10 min at room temperature. Lysates
were vortexed 15 s after addition of 80 ml of chloroform and then
centrifuged for 15 min at 12,0006 g at 4uC. The upper aqueous
phase was washed once with chloroform. Total RNA was
precipitated by addition of one volume of isopropanol, incubated
for 10 min at220uC and centrifuged for 15 min at 12,0006g and
4uC. The RNA pellet was washed twice with 80% ethanol, dried,
and complete dissolution was obtained by addition of water,
repetitive pipetting, and incubation for 15 min at 65uC. RNA
samples were stored at 280uC after quantification and quality
assessment using a QubitH fluorometer with the Quant-iTTM
RNA Assay Kit (Invitrogen) and a NanoDropTM spectrophotom-
eter (NanoDrop products, Wilmington, DE, USA).
Microarray gene expression profiling
Microarray experiments were performed by Cogenics (Morris-
ville, NC, USA) using total RNA extracted from DCs. For each
condition, three independent RNA extracts generated in one
experiment were combined to ensure homogeneity of the samples.
RNA samples were first assessed using a NanoDropTM spectro-
photometer and an Agilent bioanalyzer and then subjected to a 2-
color standard Agilent amplification labeling method. cRNA
labeled with Cy5 (control) and Cy3 (107 or 104 CFU) were
synthesized using the Quick Amp kit (Agilent) with 500 ng of total
RNA as a matrix. For each condition, 825 ng of Cy3- and Cy5-
labeled cRNA were hybridized on an Agilent Whole Human
Genome microarray 4644K (Agilent). Data were extracted from
washed and scanned microarrays using Feature Extraction
software version 10.2 (Agilent). The results were analyzed using
the BioRag database (BioResource for array genes, www.biorag.
Immunomodulation of DCs by the Probiotic Lcr35
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org). Biostatistical and bioinformatics evaluation of gene expres-
sion pattern was performed using the Resolver software (Rosetta
Biosoftware). All the microarray data were deposited according to
MIAME standards in the GeneExpression Omnibus (GEO)
database at http://www.ncbi.nlm.gov/geo/, with the accession
number GSE25699.
qRT-PCR
For each sample, 1 mg of total RNA was reverse-transcribed for
50 min at 50uC using 200 U of SuperScriptTM III Reverse
Transcriptase and 50 pmol of oligo(dT)20 primer (Invitrogen).
Resulting cDNA were diluted with two volumes (40 ml) of water
and stored at 220uC. Quantitative polymerase chain reactions
were performed using the LightCyclerH FastStart DNA Master
SYBR Green I kit as recommended by the manufacturer (Roche
Applied Science, Meylan, France) with 1 ml of matrix cDNA.
Primers are described in table S1. Reactions were performed in
triplicate with three RNA samples extracted independently. Gene
expression levels were normalized to those of the housekeeping
genes ACTB, RPLP0 and TBP, encoding respectively beta-actin,
ribosomal protein P0 and TATA box binding protein.
Maturation of the DCs in the presence of L. rhamnosus
Lcr35 and analysis by flow cytometry
On day 6, the immature DCs from each well were harvested,
pooled, centrifuged and reseeded at 16105 cells/mL. UV-killed
bacteria were then added as 10 mL medium per well to a final
concentration ranging from 103 to 107 CFU/mL, i.e. to a MOI
ranging from 0.01 to 100. Lipopolysaccharide (LPS) from
Escherichia coli (Sigma, Saint Quentin Fallavier, France) at a final
concentration of 100 ng/mL was used as positive control.
Immature dendritic cells without addition of LPS or bacteria
were used as negative control. The cells were incubated at 37uC in
5% CO2 atmosphere. After 48 h of maturation, they were
collected, centrifuged and resuspended in phosphate buffered
saline (PBS) with 1% Bovine Serum Albumin (BSA, Sigma). Cell
surfaces were stained with the appropriate fluorescence-labeled
murine antibodies: APC-Cy7-conjugated anti-CD14 (specific
molecule of the monocytes, co-receptor of the LPS), PE-
conjugated anti-CD86 (co-stimulatory molecule, activation mark-
er), FITC-conjugated anti-CD83 (specific marker of mature DCs
whose biological functions are not yet clear), PE-conjugated anti-
HLA-DR, PerCP-Cy5.5-conjugated anti-DC-SIGN (CD209,
member of the CLR family, specific marker of immature DCs),
Alexa488-conjugated anti-MR (Mannose Receptor or CD206,
member of the CLR family, specific marker of immature DCs and
macrophages) and streptavidin APC-conjugated anti-TLR4 (biotin
antibody, a LPS receptor with activation functions). Antibodies
were obtained from BD Biosciences (Le Pont de Claix, France)
except anti-MR from Biolegend (Uithoorn, The Netherlands) and
anti-HLA-DR from Beckman Coulter (Villepinte, France).
Corresponding murine isotype-matched control antibodies (BD
Biosciences and Biolegend) and non-labeled controls were
performed. The cells were analysed using BD-LSRII with
FACSDiva Software (BD Biosciences) from the Centre d’Imagerie
Cellulaire Sante´ (CICS), Universite´ d’Auvergne-Clermont1. Com-
pensation fluorescence adjustments were performed. Gates were
set on living DCs based on forward/side scatter properties. The
Figure 1. Most affected DC biological processes in response to a 3 h contact with L. rhamnosus Lcr35. The number of genes involved in
each biological process (y axis) and whose expression level is increased (black) or decreased (grey) after contact with probiotic L. rhamnosus Lcr35 at a
MOI of 10 (A) or 0.01 (B) is represented on the x axis.
doi:10.1371/journal.pone.0018735.g001
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Table 1. Expression levels of DC genes allowing the comparaison with the molecular signature of inflammation by Torri et al. [9].
Gene MOI=0.01 MOI =10 By Torri
IL6 1,090 20,661 up
IL12B 1,000 58,766 up
PDZK1IP1 1,672 1,246 up
IL4I1 1,033 1,742 up
CCL22 1,064 1,339 up
CD83 1,145 3,562 up
GADD45B 1,598 3,849 up
IL1B 1,077 177,495 up
CD40 0,966 1,907 up
NFKBIZ 1,341 5,051 up
RAB20 0,902 1,156 up
CCR7 1,112 4,953 up
TRAF1 0,956 14,687 up
STAT5A 1,014 2,638 up
ISG15 1,009 3,293 up
NFKBIA 0,998 1,750 up
IRF8 0,816 0,874 up
ICAM1 1,137 2,627 up
NFKBIB 1,224 1,904 up
TNFRSF1B 1,148 1,133 up
SQSTM1 0,998 1,025 up
IFIT1 0,887 1,748 up
SKIL 1,072 1,166 up
GNAI3 0,966 0,934 up
USP18 0,854 1,391 up
NFKB1 1,016 5,435 up
CD86 1,089 5,023 up
CLIC4 0,954 2,333 up
TAP1 0,865 1,478 up
PSME2 1,009 1,380 up
ANXA4 0,988 0,569 up
DNAJB6 0,978 1,361 up
TRAFD1 1,314 0,580 up
SERPINB9 0,817 8,334 up
CDKN1A 1,066 1,452 up
DAXX 1,227 1,931 up
EIF4EBP2 0,852 0,424 do
ELOVL6 1,385 0,732 do
TM7SF3 0,829 0,353 do
TSPAN8 1,000 1,000 do
CCNB2 0,900 0,791 do
ZNRF2 0,938 0,622 do
LTA4H 0,980 0,804 do
IL18R1 0,887 8,427 do
TEP1 0,886 0,751 do
HDAC5 1,221 0,554 do
KIF20A 1,106 2,211 do
CDC20 0,973 1,976 do
DAGLB 1,330 0,552 do
SGPP1 0,901 0,508 do
Immunomodulation of DCs by the Probiotic Lcr35
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analysis was based on a count of 3,000 DCs. The level of staining
was expressed as the mean fluorescence intensity (MFI). The culture
supernatant was collected and stored at 220uC until cytokine
analysis. Each experiment was performed at least five times.
Cytokine quantification
After 48 h of incubation, i.e. on day 8 after cells’ harvest, the
cytokines IL10 UltraSensitive, IL-12p40 and TNF-a were detected
in culture supernatants from DC culture media using Biosource
enzyme-linked immunosorbent assay (ELISA) kits (Nivelles,
Belgium). At the same time, IL-1b and IL-23 were detected with
Invitrogen ELISA Kits (France, Cergy-Pontoise) and IL-12p70
with eBioscience kit (San Diego, USA). All assays were performed
according to the manufacturer’s instructions.
Statistical analysis
Student’s matched pair t-test was used to compare means. P-
values lower than 0.05 were considered statistically significant.
Results
Transcriptional profile of dendritic cells in response to
probiotic L. rhamnosus Lcr35 by DNA microarray
All genes presenting a greater than 3-fold modification of their
expression level were selected. Expression levels of 823 genes were
increased and those of 859 genes were decreased after contact with
107 CFU (MOI, 10) of L. rhamnosus Lcr35 bacteria. In contrast, the
dendritic cells showed a weak transcriptional response after
incubation with the probiotic at a MOI of 0.01 (104 CFU), with
only 58 genes upregulated and 138 downregulated. In silico analysis
of the subcellular location of proteins encoded by the genes whose
expression was modified in response to the lactobacilli revealed
that, whatever the bacterial inoculum, most proteins belonged to
the nuclear or the membrane compartments of the cells.
Most of the genes whose expression was affected by contact with
the probiotic at a MOI of 10 were involved in four main biological
processes: 1/ immune and inflammatory responses, 2/ antigen
Gene MOI=0.01 MOI =10 By Torri
MAN2B1 1,464 1,090 do
IL1RL1 1,461 5,450 do
HLA-DMA 1,165 0,476 do
TXNDC16 1,007 0,499 do
up : upregulation signs of inflammatory response according to Torri et al.
do : downregulation signs of inflammatory response according to Torri et al.
The values discrepant with the expected response according to the model of Torri et al. are in bold.
doi:10.1371/journal.pone.0018735.t001
Table 1. Cont.
Table 2. Expression levels of genes inducing the polarization
of T lymphocytes after L. rhamnosus Lcr35-induced DC
maturation, as determined by microarray.
DC-secreted
molecule Induced T cell Gene MOI =0.01 MOI =10
TNF-a Th1 TNF 1.058 44.261
IL-12p35* Th1 IL12A* 1.000* 1.000*
IL-12p40 Th1 IL12B 1.000 58.766
IL-1b Th17 IL1B 1.077 177.495
IL-6 Th17 IL6 1.090 20.661
IL-23p19 Th17 IL23A 1.037 25.488
IL-12p40 Th17 IL12B 1.000 58.766
TGFb Th17 TGFB1 1.271 1.025
IL-4 Th2 IL4 0.664 1.175
IL-2 Th2 IL2 1.052 1.000
IL-7 Th2 IL7 0.749 1.381
OX-40L Th2 TNFS4 1.553 2.724
IL-10 Treg IL10 0.907 3.602
TGFb Treg TGFB1 1.271 1.025
retinoic acid Treg ALDH1A1 0.974 0.548
retinoic acid Treg ALDH1A2 0.973 0.687
*unexpected data.
doi:10.1371/journal.pone.0018735.t002
Table 3. Expression levels of genes of particular interest after
L. rhamnosus Lcr35-induced DC maturation, as determined by
microarray.
Genes MOI =0.01 MOI =10
IL1B 1.08 177.49
IL8 1.15 11.82
IL10 0.91 3.60
IL12A 1.00 1.00
IL12B 1.00 58.77
IL23A 1.04 25.49
TNF 1.11 30.96
CCL20 0.81 743.86
PTGS1 0.99 0.45
PTGS2 0.97 60.79
CD209 1.03 0.67
NOD2 0.98 0.47
TLR2 1.06 2.45
TLR3 1.08 0.08
CCR7 1.11 4.95
FCAR 0.55 6.55
Values corresponding to an upregulation or a downregulation of at least 3 folds
are in bold.
doi:10.1371/journal.pone.0018735.t003
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processing and presentation via major histocompatibility complex
class (MHC), 3/ intercellular signalling and 4/ signal transduction
(figure 1A). Among the three first processes, almost all changes in
expression displayed in response to L. rhamnosus Lcr35 were
increases. Although most of the observed modifications concerning
signal transduction were also gene upregulation, there were
nonetheless a notable number of genes with lower transcriptional
level. At lower MOI (0.01), the transcriptional response of
dendritic cells was barely changed after contact with probiotic
L. rhamnosus Lcr35 (figure 1B). Except for immune response, the
modifications observed in the diverse processes were essentially
repressions of gene expression and did not exceed 10-fold changes.
Comparison of our results with the Torri’s model of molecular
signature of inflammation indicated no significant effect in treated
DCs at a MOI of 0.01. Conversely, at a MOI of 10, L. rhamnosus
Lcr35 was considered as inducing a pro-inflammatory DC
phenotype by 76% (41/54) of the genes, as inducing neither a
pro-, nor an anti-inflammatory DC phenotype by 11% (6/54) and
as inducing an anti-inflammatory DC phenotype by 13% (7/54) of
the genes (table 1).
In DC genes inducing the polarization of the T lymphocytes, i.e.
mainly cytokine-encoding genes, no significant variation was
observed with the lowest MOI (0.01) whatever the gene studied,
whereas with a MOI of 10, great variations were observed (table 2).
Thus, the expression of the genes directing to a Th1 (IL12A, IL12B
and TNF) or a Th17 (IL1B, IL6, IL23A, IL12B and TGFB1) profile
were strongly upregulated (fold-changes between 20 and 177),
except IL12A and TGFB1. Expression of the DC genes directing to
a Treg (IL10, TGFB1, ALDH1A1 and ALDH1A2) or a Th2 (IL4,
IL2, IL7, TNFS4) profile were either not modified (less than 3-fold
change) or downregulated. Only IL-10 gene expression was
increased, but sparsely (3.6-fold change) compared to pro-
inflammatory cytokines-encoding genes.
qRT-PCR analysis of the probiotic effect on expression of
target genes by dendritic cells
Sixteen genes whose expression was especially affected after
contact with strain L. rhamnosus Lcr35 in microarray assays and/or
which seemed to be of particular interest for immune mucosal
response were selected for further quantitative RT-PCR assays
(table 3). None of the genes displayed a significant variation in
their transcription level after exposure of the dendritic cells to
probiotic L. rhamnosus Lcr35 at a MOI of 0.01 (figure 2). However,
the slight modifications observed were mostly repressions of gene
expression (IL8, IL10, IL12B, IL23). Conversely, with a larger
bacterial inoculum (MOI, 10), transcription of genes CCL20, IL1B,
Figure 2. qRT-PCR analysis of target genes expression in DCs after contact with the probiotic Lcr35. Gene expression levels were
determined by comparing samples exposed for 3 h to L. rhamnosus Lcr35 at a MOI of 0.01 (grey) or 10 (black) with a control sample exposed to PBS.
The names of the target genes are indicated on the x axis. The results on the y axis correspond to geometric means (6standard error of the mean) of
gene expression levels obtained from at least three independent samples.
doi:10.1371/journal.pone.0018735.g002
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IL12B and TNF was increased by about 100, 300, 400 and 200
fold respectively. These genes encode the CCL20 chemokine
(especially chemotactic for memory lymphocytes and immature
dendritic cells), the pro-inflammatory cytokines IL-1b and TNFa,
and the IL-12p40 (or IL12b subunit, which is common to the IL-
12 and IL-23 cytokines. The expression of IL23 and PTSG2 was
also increased, although less strikingly (70 and 40-fold increase,
respectively) and genes CCR7, FCAR and IL8 were upregulated
with a factor of about 9. The expression of the IL-10 encoding
gene was multiplied by 3.01, but with standard error reaching 0.84
indicating therefore a lack of significance and reproducibility. The
TLR3 gene, encoding an intracellular receptor to double strand
RNA, appeared to be repressed with its transcription levels being
about 0.15 fold the one observed in basal conditions. Finally, no or
little modification of expression was detected for the genes IL12A,
PTGS1, CD209, NOD2 and TLR2.
Overall, qRT-PCR analysis confirmed the variations in
expression levels noticed in microarray hybridization assays
resulting in an inflammatory signature in DCs treated with the
highest dose of probiotic.
Flow cytometric analysis of the probiotic effect on cell
surface phenotype of dendritic cells
DC maturation was assessed by changes in an extensive
membrane phenotype. As expected, immature DCs were charac-
terized by high levels of DC-SIGN and MR expression, together
with low expression of CD86 and CD14 (CD14 was compared
with the initial expression on monocytes before differentiation of
Figure 3. Maturation of human mo-DCs after exposure to a range of L. rhamnosus Lcr35 concentrations. The histograms show MFI
values on gated DCs. Concentrations of L. rhamnosus Lcr35 ranged from 103 to 107 CFU/mL (MOI, 0.01, 0.1, 1, 10 and 100). (A) Differential expression
on DCs of high density surface molecules CD86, DC-SIGN, MR and CD14. L. rhamnosus Lcr35 induced a dose-dependent higher expression of CD86
and a dose-dependent lower expression of DC-SIGN, MR and CD14 compared to immature DCs. (B) Differential expression on DCs of low density
surface molecules : TLR4, HLA-DR, and CD83. L. rhamnosus Lcr35 induced a dose-dependent higher expression of CD83, HLA-DR and TLR4 compared
to immature DCs. Data correspond to the mean and standard deviation of the MFI of 13 (A), and 5 (B) representative experiments. Isotypic control
values were always subtracted from the MFI of each marker. imm DCs, immature DCs; Lcr35, DCs matured with L. rhamnosus Lcr35 at different
concentrations; LPS, DCs matured with extracts of E. coli LPS.
doi:10.1371/journal.pone.0018735.g003
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DCs, data not shown) (figure 3A) and low expression of CD83,
HLA-DR and TLR4 (figure 3B). Upon maturation, L. rhamnosus
Lcr35 induced a dose-dependent higher and lower expression of
CD86 and of DC-SIGN, MR and CD14, respectively (figure 3A).
Low-dose probiotics maintained immature DC cell surface
phenotype: at MOI of 0.01 (103 CFU/mL), CD86, DC-SIGN,
MR and CD14 surface expression was not modified. In contrast,
at MOI of 0.1 (104 CFU/mL), CD86, DC-SIGN, MR and CD14
levels were slightly modified, reflecting very early activation, which
rose at higher bacterial concentrations to a MOI of 100
(107 CFU/mL). At this concentration, CD86 expression was
clearly upregulated whereas those of DC-SIGN and MR were
manifestly downregulated (figure 3A). For markers with a lower
cell surface density, such as CD83, HLA-DR and TLR4,
L. rhamnosus Lcr35 also induced a dose-dependent higher surface
expression as detected by flow cytometry (figure 3B). These results
closely corroborate those obtained by studying DC gene
expression with regard to high surface density markers (4/4), but
not for low dose density markers (1/3) (table 4). As expected, in the
control experiment, LPS-induced DCs expressed a phenotype,
called fully mature DCs, with a very high level of CD86, decreased
levels of DC-SIGN, MR and CD14 (figure 3A) associated with
increases in the synthesis of markers with low surface density such
as CD83, HLA-DR and TLR4 (figure 3B). The L. rhamnosus
Lcr35-induced phenotype was thus intermediate between that of
immature DCs and that of fully mature LPS-induced DCs, a so-
called semi-mature DCs phenotype.
Cytokine production induced by L. rhamnosus Lcr35-
matured DCs
Six cytokines whose encoding gene expression was especially
affected by contact with strain L. rhamnosus Lcr35 in quantitative
RT-PCR assays and/or which seemed to be of particular interest
for the understanding of the DC response were selected for ELISA
measurements. Compared to untreated immature DCs, a strong
dose-dependent increase in the production of IL-12p40 and TNF-
a was induced by L. rhamnosus Lcr35 and, to a lesser extent, in the
production of IL-10 (figure 4). The fold changes determined by
comparing the level of cytokines produced by 107 CFU/mL
L. rhamnosus Lcr35-treated DCs (i.e MOI, 100) with that of
immature DCs were respectively 73 for IL-12p40, 38 for TNF-a
and, merely, 4 for IL-10 production. These great differences are
also in favour of a strongly pro-inflammatory profile induced by
the probiotic at high concentrations.
Since IL-12p40 is the common subunit shared by IL-12p70 (or
IL-12) and IL-23, we next examined their specific levels (figure 5).
IL-12p70 was not or barely detectable in immature DCs and in
L. rhamnosus Lcr35-treated DCs at MOI ranging from 0.01 to 1
(from 103 till 105 CFU/mL). At MOI of 10 (106 CFU/mL), this
cytokine became detectable and, at MOI of 100 (107 CFU/mL),
its concentration exceeded the LPS-induced level (MOI,100/LPS-
induction, fold change = 3). IL-23 was also not or barely detectable
in L. rhamnosus Lcr35-treated DCs with MOI ranging from 0.01 to
1 (figure 5). At higher L. rhamnosus MOI, the concentrations of IL-
23 increased, but stayed at the level of LPS-treated DCs
(MOI,100/LPS-induction, fold change = 1). Finally, we performed
IL-1b measurements. The protein was once again not detectable
at low concentrations, but was produced with the highest MOIs
(MOI, 10 or 100), in agreement with the data from molecular
analysis (microarray and RT-PCR). The combined increases of
TNF-a, IL-12p40, IL-12p70, IL-1b and IL-23 indicated that
L. rhamnosus Lcr35 induced a pro-Th1/Th17 DC phenotype.
Discussion
Probiotics have been shown to exert health benefits, mostly in
the prevention and treatment of enteric infectious and inflamma-
tory diseases [18–21]. However, understanding how these bacteria
contribute to human health remains a major challenge. One main
difficulty is to assess their interactions with components of the
intestinal immune system, especially the DCs, a key player in
mucosal immunity. Specific probiotic strains, in particular
Bifidobacterium and Lactobacillus strains, have been shown to interact
with DCs and to induce strain-specific effects. Indeed, great
variations in the ability of different strains of Lactobacillus to induce
DC production of key cytokines such as IL-12 and IL-10 were
observed, resulting in either pro-inflammatory or, conversely, anti-
inflammatory patterns [22]. However, there are great differences
between studies in bacteria/DCs ratio. The eventuality that these
variations of MOI affected the DCs maturation process, and
therefore their response to the probiotic strains, cannot be
excluded [14,23–27].
Lactobacillus rhamnosus Lcr35 is a well characterized probiotic
strain which has been used in clinical practice for more than 50
years. The bacteriological effects of the strain have been
documented in the past decade [15,28,29] but little is known
about its interactions with the immune system. To provide insight
into the immunological properties of the specific probiotic
L. rhamnosus Lcr35 strain, we studied its interactions with immature
DCs, using a large range of bacterial concentrations and both
genomic and phenotypic approaches.
Gene array analysis is a new approach to evaluate the probiotic
effects on immune cells [30], which provided an overall view of the
changes in gene expression patterns of probiotic-matured DCs
resulting from contact with different bacterial concentrations. Our
results showed great dose-dependent variations. At a MOI of 10,
the overexpression of 823 genes (with a 3-foldchange threshold)
most of which are involved in the immune response was observed
together with a decrease in the expression of 859 other genes,
whereas at a lower MOI (0.01), the expression of only 139 genes
was modified. In addition, the analysis of the gene expression
profile according to the model of Torri et al. identified an
inflammatory signature in DCs treated with the highest dose of
probiotic, whereas at lower MOI, L. rhamnosus Lcr35 induced
Table 4. Expression levels of DC genes at a MOI of 10, as
determined by microarray, compared to MFI variations of
membrane markers detected by flow cytometry.
Gene Microarray (Fold changes) Cytometry data (MFI)
CD86 5.023 hi up
CD209-DC-SIGN 0.536 hi do
MRC1L1-CD206 0.361 hi do
CD14 0.325 hi do
CD83 3.562 lo up
HLA-DRA 0.456 lo up
TLR4 0.423 lo up
hi : marker of high membrane density
lo : marker of low membrane density
up : upregulation of the cytometric marker
do : downregulation of the cytometric marker
The discrepant values between the two techniques are in bold.
doi:10.1371/journal.pone.0018735.t004
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neither anti-inflammatory nor pro-inflammatory effects. The very
different profiles obtained according to the bacterial inocula in this
work should lead us to be more cautious in the interpretation of
in vitro data when a single dose of probiotics is used. This also raises
the question of what happens in vivo. Most commercial
preparations of probiotics are taken orally and little is known
about the remaining concentration of probiotics in contact with
the mucosal DCs when they reach the small intestine or the colon.
Figure 4. Cytokine production of human mo-DCs after 48 h exposure to a range of L. rhamnosus Lcr35 concentrations. Concentrations
of L. rhamnosus Lcr35 ranged from 103 to 107 CFU/mL (MOI, 0.01 to 100). L. rhamnosus Lcr35 induced a dose-dependent production of IL-12p40, TNF-
alpha and IL-10. The production of IL-12 and TNF-alpha pro-inflammatory cytokines was much higher than that of IL-10. Data correspond to the mean
and standard deviation of five independent experiments.
doi:10.1371/journal.pone.0018735.g004
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Figure 5. Cytokine production of human mo-DCs after 48 h exposure to a range of L. rhamnosus Lcr35 concentrations. Concentrations
of L. rhamnosus Lcr35 ranged from 103 to 107 CFU/mL (MOI, 0.01 to 100). L. rhamnosus Lcr35 induced a dose-dependent production of IL-12p70 (pro-
Th1), IL-23 (pro-Th17) and IL-1b (pro-Th17). Data correspond to the mean and standard deviation of six independent experiments.
doi:10.1371/journal.pone.0018735.g005
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Depending on the doses ingested and their frequency, the effects
induced by the probiotics could be very different and suitable for
the treatment of different diseases, needing to be fought by pro- or
anti-inflammatory responses.
Analysis of the genes involved in the orientation of the T cell
response using microarray data revealed that L. rhamnosus Lcr35
was able to induce a strong pro-Th17 DC response. Of the five
pro-Th17 genes tested, only the TGFb gene was not upregulated,
but, unlike in murine models, the role of TGFb in Th17 induction
in humans is still a contentious issue [31]. Similarly, qRT-PCR
analysis of the genes indicated that L. rhamnosus Lcr35 at high
concentrations was strongly pro-inflammatory, with a major pro-
Th17 DC type of response. For the pro-Th1 response,
contradictory results were obtained in microarray analysis
regarding the two subunits of IL-12, with an increase in IL-
12p40 gene expression (shared by IL-12 and IL-23) but no
variation in IL-12p35 (specific of IL-12) messenger level. The
upregulation of IL-12p40 expression could be corroborated by the
strong increase in the expression of the TNF-a encoding gene, but
the absence of variation, whatever the MOI, for the IL12p35-
encoding gene was rather unexpected. The qRT-PCR results
regarding the pro-Th1 genes were in agreement with these
findings, with a strong increase in IL-12p40 and TNF-a mRNAs,
but only a low increase in the case in IL-12p35.
Transcription analysis data was further completed by the
determination of the DCs phenotype, including analysis of
cytokine production. The upregulated production of TNF-a, IL-
1b, IL-23, IL-12p40 and IL-12p70 cytokines as measured by
ELISA showed that this probiotic effectively enhanced pro-
inflammatory and pro-Th17 immune responses, but also pro-
Th1 response. Lcr35 therefore behaves like many species of
lactobacilli, L. casei, L. gasseri, L. johnsonii, L. reuteri, and L. rhamnosus
GG, previously described as pro-Th1 inducers [23,32,33]. To our
knowledge, this is the first time a probiotic Lactobacillus has been
reported to have a pro-Th17 effect on DC maturation, but this
was not tested in previous studies. Obtaining a combined response
both pro-Th1 and pro-Th17 is not surprising, because Th1 and
Th17 responses are two types of pro-inflammatory response which
may be combined and acte together in the response against many
pathogens [34].
Niess et al. recently reported that in mice, enteric flora induced
the expansion of a specific type of lamina propria DCs, the
CX3CR1+ DCs, which led to a mucosal inflammatory response
and preferentially induced Th1/Th17 T cell differentiation [35].
These DCs are CD14+ and derive from monocytes under the
control of GM-CSF [36,37]. It is therefore tempting to postulate
that the L. rhamnosus Lcr35 strain-induced DCs are related to these
murine DCs. Indeed, in our experiments, human L. rhamnosus
Lcr35-treated DCs were generated in vitro from monocytes by
culturing PBMCs with GM-CSF (and IL-4) [38–39], and were
phenotypically CD14+. In addition, as CX3CR1+ DCs, they
supported Th1/Th17 T cell differentiation.
In the murine model, induction of Th1/Th17 cells by
CX3CR1+ DCs initiates the host defence against intestinal
pathogens, such as Salmonella [40]. L. rhamnosus Lcr35, by acting
on DCs and facilitating Th1/Th17 T cell differentiation, could
therefore indirectly participate in the defense against pathogens.
Elsewhere, the main clinical indications of L. rhamnosus Lcr35
probiotic are related to its anti-infectious properties, in particular
in infectious diarrhea and in microbial vaginosis [17,41,42]. Our
results are based on in vitro experiments and need to be assessed in
in vivo studies. In addition, our flow cytometry data indicated that
L. rhamnosus Lcr35 induced semi-maturation of DCs with an
upregulation of the membrane expression of HLA-DR, CD86 and
CD83, combined with upregulation of CCR7 observed in qRT-
PCRs. Taken together, these results demonstrate that, compared
to immature DCs, probiotic-treated DCs have a higher potential
of antigen presentation, costimulation and migration, and
therefore should have a greater ability to induce an immune
response of an effector type, as required when encoutering
pathogens.
The Lcr35 probiotic might also be useful in the treatment of
allergic disorders. A recent work showed that oral treatment with
Lcr35 prior to sensitization can attenuate airway inflammation
and hyperreactivity in a murine model of allergic airway
inflammation, suggesting that Lcr35 has the potential for
preventing asthma [43]. In recent years, many studies on the
use of probiotics in the prevention or treatment of allergy have
focused on their role, by acting on monocytes, PBMCs or DCs, in
the production of IL-10 and in the generation of regulatory cells
[13,44–47]. Smits et al. demonstrated that both L. reuteri and
L. casei, but not L. plantarum, bind the DC-SIGN on membrane
DCs and that this ligation can actively prime DCs which
produced IL-10 to induce Treg cells. As L. rhamnosus Lcr35
induced only a very low increase in IL-10 and only at high
concentrations, and as it did not modulate the gene expression of
TGFb and of the enzymes allowing retinoic acid synthesis, it is
very unlikely that it induced Tregs. Thus, the anti-allergic
mechanism of action of L. rhamnosus Lcr35 probably does not
involve the Tregs regulatory pathway. Since L. rhamnosus Lcr35
modulates the Th1/Th2 balance towards the Th1(/Th17)
response in DCs, it could counter-regulate the impaired cytokine
profile observed in IgE-dependent allergies, characterized by an
imbalance of the Th1/Th2 response towards the Th2 profile.
Future clinical studies are necessary to investigate this possibility.
Combined, our findings show that the probiotic L. rhamnosus
Lcr35 induces a dose-dependent immunomodulation of human
DCs leading, at high bacterial doses, to the semi-maturation of the
cells and a strong synthesis of pro-Th1/Th17 cytokines. These
results open up broader prospects regarding the clinical indications
in which this probiotic could be used, to strengthen the immune
defences in the case of infections or in the immunomodulation of
IgE-dependent allergic diseases.
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Figure S1 Cytometric analysis of the DC-SIGN expres-
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expressing the DC-SIGN, was always above 90%.
(PPT)
Table S1 Primers used in qRT-PCRs.
(DOC)
Acknowledgments
We thank Julie Falenta and Mathilde Cazaux for their excellent technical
work. We also thank the CICS (Centre d’Imagerie Cellulaire Sante´) of
Clermont-Ferrand, and in particular Christelle Blavignac and Claire
Szczepaniak. We are also grateful to Jean-Louis Joseph Gachancard-Bouya
for his contribution to this work.
Author Contributions
Conceived and designed the experiments: BE AT CF SC. Performed the
experiments: BE AD SC NC JA. Analyzed the data: BE AT CF SC.
Contributed reagents/materials/analysis tools: BE SC CF AT. Wrote the
paper: BE SC CF AT.
Immunomodulation of DCs by the Probiotic Lcr35
PLoS ONE | www.plosone.org 11 April 2011 | Volume 6 | Issue 4 | e18735
References
1. Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN (2007) Balancing
between immunity and tolerance: an interplay between dendritic cells,
regulatory T cells, and effector T cells. J Leukoc Biol 82: 1365–74.
2. Quah BJ, O’Neill HC (2005) Maturation of function in dendritic cells for
tolerance and immunity. J Cell Mol Med 9: 643–54.
3. Shortman K, Naik SH (2007) Steady-state and inflammatory dendritic-cell
development. Nat Rev Immunol 7: 19–30.
4. Wu L, Liu YJ (2007) Development of dendritic-cell lineages. Immunity 26:
741–50.
5. Sabatte´ J, Maggini J, Nahmod K, Amaral MM, Martı´nez D, et al. (2007)
Interplay of pathogens, cytokines and other stress signals in the regulation of
dendritic cell function. Cytokine Growth Factor Rev 18: 5–17.
6. Mazzoni A, Segal DM (2004) Controlling the Toll road to dendritic cell
polarization. J Leukoc Biol 75: 721–30.
7. Zhu J, Paul WE (2008) CD4 T cells: fates, functions, and faults. Blood 112:
1557–69.
8. Zhu J, Paul WE (2010) Heterogeneity and plasticity of T helper cells. Cell Res
20: 4–12.
9. Torri A, Beretta O, Ranghetti A, Granucci F, Ricciardi-Castagnoli P, et al.
(2010) Gene expression profiles identify inflammatory signatures in dendritic
cells. PLoS One 5: e9404.
10. Corthe´sy B, Gaskins HR, Mercenier A (2007) Cross-talk between probiotic
bacteria and the host immune system. J Nutr 137: 781–90.
11. Drakes M, Blanchard T, Czinn S (2004) Bacterial probiotic modulation of
dendritic cells. Infect Immun 72: 3299–309.
12. Foligne B, Zoumpopoulou G, Dewulf J, Ben Younes A, Chareyre F, et al. (2007)
A key role of dendritic cells in probiotic functionality. PLoS ONE 2: e313.
13. Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K, et al. (2005)
Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by
modulating dendritic cell function through dendritic cell-specific intercellular
adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol 115:
1260–7.
14. Zeuthen LH, Christensen HR, Frøkiaer H (2006) Lactic acid bacteria inducing a
weak interleukin-12 and tumor necrosis factor alpha response in human
dendritic cells inhibit strongly stimulating lactic acid bacteria but act
synergistically with gram-negative bacteria. Clin Vaccine Immunol 13: 365–75.
15. Forestier C, De Champs C, Vatoux C, Joly B (2001) Probiotic activities of
Lactobacillus casei rhamnosus: in vitro adherence to intestinal cells and
antimicrobial properties. Res Microbiol 152: 167–73.
16. Coudeyras S, Marchandin H, Fajon C, Forestier C (2008) Taxonomic and
strain-specific identification of the probiotic strain Lactobacillus rhamnosus 35
within the Lactobacillus casei group. Appl Environ Microbiol 74: 2679–89.
17. Coudeyras S, Jugie G, Vermerie M, Forestier C (2008) Adhesion of human
probiotic Lactobacillus rhamnosus to cervical and vaginal cells and interaction
with vaginosis-associated pathogens. Infect Dis Obstet Gynecol 2008: 549640.
18. Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, et al. (2006) Efficacy of
probiotics in prevention of acute diarrhoea: a meta-analysis of masked,
randomised, placebo-controlled trials. Lancet Infect Dis 6: 374–82.
19. Hedin C, Whelan K, Lindsay JO (2007) Evidence for the use of probiotics and
prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr
Soc 66: 307–15.
20. Deshpande G, Rao S, Patole S, Bulsara M (2010) Updated meta-analysis of
probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics
125: 921–30.
21. Camilleri M (2008) Probiotics and irritable bowel syndrome: rationale,
mechanisms, and efficacy. J Clin Gastroenterol 42: S123–5.
22. Lebeer S, Vanderleyden J, De Keersmaecker SC (2008) Genes and molecules of
lactobacilli supporting probiotic action. Microbiol Mol Biol Rev 72: 728–64.
23. Christensen HR, Frøkiaer H, Pestka JJ (2002) Lactobacilli differentially
modulate expression of cytokines and maturation surface markers in murine
dendritic cells. J Immunol 168: 171–8.
24. Baba N, Samson S, Bourdet-Sicard R, Rubio M, Sarfati M (2008) Commensal
bacteria trigger a full dendritic cell maturation program that promotes the
expansion of non-Tr1 suppressor T cells. J Leukoc Biol. Aug;84(2): 468–76.
25. Hart AL, Lammers K, Brigidi P, Vitali B, Rizzello F, et al. (2004) Modulation of
human dendritic cell phenotype and function by probiotic bacteria. Gut 53:
1602–9.
26. Dogi CA, Galdeano CM, Perdigo´n G (2008) Gut immune stimulation by non
pathogenic Gram(+) and Gram(2) bacteria. Comparison with a probiotic strain.
Cytokine 41: 223–31.
27. Ongol MP, Iguchi T, Tanaka M, Sone T, Ikeda H, et al. (2008) Potential of
selected strains of lactic acid bacteria to induce a Th1 immune profile. Biosci
Biotechnol Biochem 72: 2847–57.
28. de Champs C, Maroncle N, Balestrino D, Rich C, Forestier C (2003) Persistence
of colonization of intestinal mucosa by a probiotic strain, Lactobacillus casei
subsp. rhamnosus Lcr35, after oral consumption. J Clin Microbiol 41: 1270–3.
29. Forestier C, Guelon D, Cluytens V, Gillart T, Sirot J, et al. (2008) Oral probiotic
and prevention of Pseudomonas aeruginosa infections: a randomized, double-
blind, placebo-controlled pilot study in intensive care unit patients. Crit Care 12:
R69.
30. van Baarlen P, Troost F, van der Meer C, Hooiveld G, Boekschoten M, et al.
Microbes and Health Sackler Colloquium: Human mucosal in vivo transcrip-
tome responses to three lactobacilli indicate how probiotics may modulate
human cellular pathways. Proc Natl Acad Sci U S A [Epub ahead of print] 2010.
31. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S (2009) Human Th17
cells: are they different from murine Th17 cells? Eur J Immunol 39: 637–40.
32. Mohamadzadeh M, Olson S, Kalina WV, Ruthel G, Demmin GL, et al. (2005)
Lactobacilli activate human dendritic cells that skew T cells toward T helper 1
polarization. Proc Natl Acad Sci U S A 102: 2880–5.
33. Pochard P, Gosset P, Grangette C, Andre C, Tonnel AB, et al. (2002) Lactic acid
bacteria inhibit TH2 cytokine production by mononuclear cells from allergic
patients. J Allergy Clin Immunol 110: 617–23.
34. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, et al. (2007)
Phenotypic and functional features of human Th17 cells. J Exp Med 204:
1849–61.
35. Niess JH, Adler G (2010) Enteric flora expands gut lamina propria CX3CR1+
dendritic cells supporting inflammatory immune responses under normal and
inflammatory conditions. J Immunol 184: 2026–37.
36. Bogunovic M, Ginhoux F, Helft J, Shang L, Hashimoto D, et al. (2009) Origin of
the lamina propria dendritic cell network. Immunity 31: 513–25.
37. Varol C, Vallon-Eberhard A, Elinav E, Aychek T, Shapira Y, et al. (2009)
Intestinal lamina propria dendritic cell subsets have different origin and
functions. Immunity 31: 502–12.
38. Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by
cultured human dendritic cells is maintained by granulocyte/macrophage
colony-stimulating factor plus interleukin 4 and downregulated by tumor
necrosis factor alpha. J Exp Med 179: 1109–18.
39. Romani N, Reider D, Heuer M, Ebner S, Ka¨mpgen E, et al. (1996) Generation
of mature dendritic cells from human blood. An improved method with special
regard to clinical applicability. J Immunol Methods 196: 137–51.
40. Arques JL, Hautefort I, Ivory K, Bertelli E, Regoli M, et al. (2009) Salmonella
induces flagellin- and MyD88-dependent migration of bacteria-capturing
dendritic cells into the gut lumen. Gastroenterology 137: 579–87.
41. Vidal M, Forestier C, Charbonnel N, Henard S, Rabaud C, et al. (2010)
Probiotics and intestinal colonization by vancomycin-resistant enterococci in
mice and humans. J Clin Microbiol 48: 2595–8.
42. Fang SB, Lee HC, Hu JJ, Hou SY, Liu HL, et al. (2009) Dose-dependent effect
of Lactobacillus rhamnosus on quantitative reduction of faecal rotavirus
shedding in children. J Trop Pediatr 55: 297–301.
43. Yu J, Jang SO, Kim BJ, Song YH, Kwon JW, et al. (2010) The Effects of
Lactobacillus rhamnosus on the Prevention of Asthma in a Murine Model.
Allergy Asthma Immunol Res 2: 199–205.
44. Niers LE, Hoekstra MO, Timmerman HM, van Uden NO, de Graaf PM, et al.
(2007) Selection of probiotic bacteria for prevention of allergic diseases:
immunomodulation of neonatal dendritic cells. Clin Exp Immunol 149: 344–52.
45. Helwig U, Lammers KM, Rizzello F, Brigidi P, Rohleder V, et al. (2006)
Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory
cytokines in peripheral blood mononuclear cells. World J Gastroenterol 12:
5978–86.
46. Lammers KM, Brigidi P, Vitali B, Gionchetti P, Rizzello F, et al. (2003)
Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response
in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol
38: 165–72.
47. Konstantinov SR, Smidt H, de Vos WM, Bruijns SC, Singh SK, et al. (2008) S
layer protein A of Lactobacillus acidophilus NCFM regulates immature
dendritic cell and T cell functions. Proc Natl Acad Sci U S A 105: 19474–9.
Immunomodulation of DCs by the Probiotic Lcr35
PLoS ONE | www.plosone.org 12 April 2011 | Volume 6 | Issue 4 | e18735
